Discussion between Stéphane Bancel, CEO of Moderna & Yves Mirabaud, our Senior Managing Partner

Do you want to know how Moderna went from a start-up status to a household name which could save millions of life in 2021 from Covid-19 ?
Do you know that their ambition is to become the most valuable LifeScience company in the world by 2030 ?
How and when did it all start 10 years ago ? What is the technology disruption here ? How can the MRNA technology platform developed by Moderna be useful to cure other disease going forward ?
And what is Moderna’s historical link with Switzerland ?

To find out more, listen to this fascinating discussion between Stéphane Bancel, CEO of Moderna and Yves Mirabaud, Senior Managing Partner of Mirabaud recorded on March 22nd 2021.

#covid19 #vaccine #moderna #mRNA #science

***

00:00 - Introduction
00:48 - How did it all start?
04:52 - mRNA: a game changer technology
07:01 - Moderna and Switzerland
09:50 - Moderna and Lonza
12:13 - Moderna and COVID-19
18:17 - Evolution with variants
23:02 - Future Moderna drugs, innovations and market opps
27:20 - Moderna's growth potential
29:19 - Moderna's challenges
32:25 - 2030 Moderna vision
39:25 - Moderna's valuation

[paulhampel]

The ROI and likelihood of commercial success are the most doubted and misunderstood issues for analysts. The more Bancel can convince analysts of these points the more he can establish the true value of Moderna. I would love to see the point in future slides in coming presentations. As always, thank you for all of your great work Stéphane Bancel.